A Bayesian paradigm for decision-making in proof-of-concept trials

Area of Science:

• Drug Development
• Decision Analysis
• Biostatistics

Background:

• Drug development decisions, particularly at the proof-of-concept stage, involve significant uncertainty and risk.
• High Phase 3 trial failure rates necessitate improved decision-making strategies.
• Current methods often rely on statistical significance, which may not fully support critical go/no-go decisions.

Purpose of the Study:

• To present a flexible Bayesian quantitative decision-making paradigm for drug development.
• To provide a framework for designing proof-of-concept trials that optimize decision-making capabilities.
• To compare the proposed operating characteristics framework with traditional p-value-based methods.

Main Methods:

• Developed a Bayesian decision-making paradigm evaluating evidence against a multilevel target product profile.
• Introduced a framework for operating characteristics to guide proof-of-concept trial design.
• Considered sample size, interim futility analysis, and historical data incorporation.

Main Results:

• The proposed Bayesian paradigm offers a flexible approach to evidence evaluation.
• Operating characteristics framework enables trial design focused on supporting decisions, not just statistical significance.
• Demonstrated superiority of operating characteristics over traditional p-value-based methods.

Conclusions:

• The Bayesian quantitative decision-making paradigm enhances the strategic design of proof-of-concept trials.
• This approach provides a more robust method for weighing risk and evidence in drug development.
• Improved trial design can lead to more informed decisions, potentially reducing Phase 3 failure rates.